Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,799 total articles

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Assembly Biosciences has completed a registered public offering of approximately 3.9 million common shares and 415,000 pre-funded warrants, raising gross proceeds of $115 million. The company plans to use the funds to advance clinical development of its therapeutic candidates targeting serious viral and liver diseases and for general corporate purp…

Zscaler Announces Strong Third-Quarter Fiscal 2026 Results

Zscaler Announces Strong Third-Quarter Fiscal 2026 Results

Zscaler Inc. announced its Q3 fiscal 2026 results with revenue and ARR growth of 25% YoY, record profitability with non-GAAP operating margin at 23%, and strong cash flow performance. The company highlighted strategic moves targeting AI-driven cybersecurity enhancements, including acquisitions and partnerships. Guidance for fiscal 2026 was raised, …

Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026

Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026

Apogee Therapeutics will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart, a novel biologic targeting moderate-to-severe atopic dermatitis (AD), on May 27, 2026, followed by a webcast and conference call. The company aims to advance treatments in inflammatory and immunology markets with optimized antibody therapies, addressing…

Firefly Aerospace Wins $75 Million NASA JPL MoonFall Subcontract to Deliver Drones to the Moon’s South Pole

Firefly Aerospace Wins $75 Million NASA JPL MoonFall Subcontract to Deliver Drones to the Moon’s South Pole

Firefly Aerospace has secured a $75 million subcontract from NASA's Jet Propulsion Laboratory to deliver four drones to the Moon's south pole as part of NASA's MoonFall mission, aiming for launch no earlier than 2028. The mission supports NASA's long-term lunar exploration and infrastructure goals under the Artemis program. Firefly will utilize its…

Brunswick Corporation Establishes a New Company Record with 15 Boating Industry 2026 Top Product Awards

Brunswick Corporation Establishes a New Company Record with 15 Boating Industry 2026 Top Product Awards

Brunswick Corporation announced it has earned 15 Boating Industry Magazine Top Product Awards for 2026, the highest number it has received in a single year. The awards span 13 different Brunswick brands and recognize excellence in boats, propulsion, vessel control, and marine electronics. CEO Dave Foulkes highlighted the company's focus on consumer…

BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

BioRestorative Therapies, Inc. has completed dosing in its fully enrolled Phase 2 clinical trial for BRTX-100, an autologous stem cell therapy targeting chronic lumbar disc disease. The randomized, double-blind, sham-controlled study treated 99 patients and is now advancing to blinded follow-up, with topline safety and efficacy data expected in Q2 …

Gauzy Ltd. Announces Receipt of Nasdaq Notice Regarding Delayed Filing of Annual Report on Form 20-F

Gauzy Ltd. Announces Receipt of Nasdaq Notice Regarding Delayed Filing of Annual Report on Form 20-F

Gauzy Ltd., a Nasdaq-listed vision and light control technology company, announced it received a Nasdaq notice due to delayed filing of its 2025 Annual Report Form 20-F. The company has 60 days to submit a compliance plan and may be granted up to 180 days to regain compliance. Failure to meet Nasdaq's listing standards could lead to delisting. Gauz…